PMID: 22358358Feb 24, 2012Paper

Gram-negative osteomyelitis: clinical and microbiological profile

The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases
Vladimir Cordeiro de CarvalhoAna Lúcia Lei Munhoz Lima

Abstract

Despite the growing interest in the study of Gram-negative bacilli (GNB) infections, very little information on osteomyelitis caused by GNB is available in the medical literature. To assess clinical and microbiological features of 101 cases of osteomyelitis caused by GNB alone, between January 2007 and January 2009, in a reference center for the treatment of high complexity traumas in the city of São Paulo. Most patients were men (63%), with median age of 42 years, affected by chronic osteomyelitis (43%) or acute osteomyelitis associated to open fractures (32%), the majority on the lower limbs (71%). The patients were treated with antibiotics as inpatients for 40 days (median) and for 99 days (median) in outpatient settings. After 6 months follow-up, the clinical remission rate was around 60%, relapse 19%, amputation 7%, and death 5%. Nine percent of cases were lost to follow-up. A total of 121 GNB was isolated from 101 clinical samples. The most frequently isolated pathogens were Enterobacter sp. (25%), Acinetobacter baumannii (21%) e Pseudomonas aeruginosa (20%). Susceptibility to carbapenems was about 100% for Enterobacter sp., 75% for Pseudomonas aeruginosa and 60% for Acinetobacter baumannii. Osteomyelitis caused by GNB re...Continue Reading

References

Nov 25, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E F BerbariD R Osmon
Nov 1, 2003·The Spine Journal : Official Journal of the North American Spine Society·Larry T KhooRichard G Fessler
Jul 20, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Erica N JohnsonClinton K Murray
Mar 21, 2008·The New England Journal of Medicine·L Silvia Munoz-Price, Robert A Weinstein
Jun 28, 2008·The New England Journal of Medicine·Ana L LimaAdriana P Paula
Aug 21, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pang-Hsin HsiehSteve W Ueng
Aug 21, 2009·The New England Journal of Medicine·Jose L Del Pozo, Robin Patel
May 14, 2010·The New England Journal of Medicine·Anton Y Peleg, David C Hooper

❮ Previous
Next ❯

Citations

Sep 12, 2013·Interdisciplinary Perspectives on Infectious Diseases·Ana Lucia L LimaMarcelo B Rodrigues
Mar 5, 2016·Materials·Dina Ahmed MosselhySimo-Pekka Hannula
Dec 16, 2016·Clinical Microbiology Reviews·Darren WongBrad Spellberg
Feb 7, 2018·Journal of Laboratory Physicians·Lakshmi VemuPadmasri Chavali

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.